Canada’s Drug Agency has released a draft recommendation for lecanemab funding

Canada’s Drug Agency has released a draft recommendation recommending against public reimbursement for lecanemab, a new disease-modifying therapy for early-stage Alzheimer's disease that was conditionally approved by Health Canada in the fall.

"For people who were hoping to access the drug, this will come as hard news, and we’ re here to help ensure their voices are heard as we advocate for equitable access to new treatments,” said Alzheimer Society of BC and Yukon CEO Jennifer Lyle. “For others affected by dementia, their supporters and members of the dementia research community, this remains a hopeful time as new treatments able to change the course of the disease emerge. We need to do everything in our power now to address our health-care system capacity and inequities to ensure that when a treatment is more widely financially accessible, we can actually deliver it. We have our work cut out for us.”

Among the systemic issues and equity considerations cited in the Agency’s decision were the need for improved access to a timely diagnosis and clear pathways for care, including for groups who often face barriers to accessing the health-care system due to geography, gender or identity. The draft recommendation also referenced uncertain benefits and safety concerns.

This recommendation is disappointing for many people living with Alzheimer’s disease and their families, however, the Agency’s decision is open for feedback until March 5, when a final recommendation is determined. The Alzheimer Society of BC and Yukon will continue to advocate for equitable access to care, supports and emerging treatment options, while amplifying the voices of people with lived experience. We share in the disappointment this recommendation carries, but we also acknowledge the reasoning behind it and respect the Agency’s process.